Ledger.

Chief Executive, Glyscend

Ashish Nimgaonkarand

Coverage

Stories naming Ashish Nimgaonkarand. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Unnamed stage $29m

Adelaide Type 2 Diabetes researchers zero in on an 'operation in a pill'

Glyscend Therapeutics, an Adelaide-Baltimore biotech, is recruiting volunteers for phase 1 trials of GLY-200, a pill mimicking gastric bypass for type 2 diabetes, developed with $29 million from MRCF, Santé Ventures and Breakout Labs.

Brandon BioCatalyst portfolio Tue 3 Aug 2021 GlyscendBrandon CapitalCMAXPayPalRoyal Adelaide HospitalUniversity of AdelaideBreakout LabsMedical Research Commercialisation Fund (MRCF)Santé VenturesAshish NimgaonkarandProfessor Chris RaynerPeter Thiel

Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio

Something wrong? Tell us